Product news from the 06/27/06 News Brief

Share this article:
Abbott announced that the FDA has approved its Humira Pen, a new device for administering Humira (adalimumab) treatment for moderate to severe rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Humira Pen will be available to US patients beginning in August.   The FDA has approved sales of Johnson & Johnson's Prezista, to treat HIV infection. Also known as TMC114, Prezista is a protease inhibitor designed to treat resistant strains of the HIV virus that causes AIDS. The FDA has approved Genentech’s Avastin (bevacizumab) in combination with intravenous 5-fluorouracil (5-FU)-based chemotherapy for second-line metastatic colorectal cancer. Avastin is also approved as a first-line treatment of metastatic colorectal cancer (CRC) in combination with intravenous 5-FU-based chemotherapy. The FDA has approved the expanded indication of Allergan's once-daily prescription eye drop Lumigan (bimatoprost ophthalmic solution) 0.03% as a first-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension. The FDA has approved Endo Pharmaceuticals' NDAs for Opana ER (oxymorphone hydrochloride) extended-release tablets and Opana (oxymorphone hydrochloride) immediate-release tablets. Opana ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Opana is indicated for the relief of moderate to severe acute pain for which the use of an opioid is appropriate.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies